Dendritic cells-based immunotherapy to be commercialized next year

Published: 2004-04-06 06:55:00

Updated: 2004-04-06 06:55:00

Keunwha Pharm said recently that its dendritic cells-based immunotherapy, which was developed in collaboration with Binex and research team of Pusan University last November, is to be launched next year after completion of Phase I/II clinical trials following the approval from the Korea Food and ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK